Immix Biopharma

ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications.

Content by Immix Biopharma

| 1 min read

byImmix Biopharma

Fresh faces blazing a new trail in oncology

A new kid on the block flips the script using a systems biology-inspired tissue-specific approach against metastatic cancer that normalizes the tumor microenvironment.

Industry Perspectives

Page 1 of 1 - 1 Total Items

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Scientific illustration of a cell releasing exosomes: small, spherical extracellular vesicles budding from and detaching off the cell’s plasma membrane into the surrounding space, shown as tiny capsule-like structures emerging from the cell surface.

Lock-in unmatched EV characterization with Leprechaun

Learn how to distinguish true extracellular vesicles from similarly sized particles using affinity capture and immunofluorescence.

Webinars

Close-up of a scientist’s hands typing on a laptop next to a microscope in a laboratory setting.

A scientist's guide to electronic laboratory notebook selection

Explore how a needs-driven approach to electronic laboratory notebook selection can improve data integrity, reproducibility, and scientific continuity.

Articles